Emir Sandhu
Managing Director at Sandbox Healthcare & The Blue Venture Fund
San Francisco, California
Overview
Work Experience
Managing Director
2019 - Current
The Blue Venture Fund is a unique collaboration among Blue Cross Blue Shield (BCBS) companies, the Blue Cross Blue Shield Association (BCBSA), and Sandbox, to which thirty-five BCBS companies have committed approximately $900 million across four funds. The Blue Venture Fund invests in promising emerging companies of strategic relevance to Blue Cross and/or Blue Shield companies and provides the portfolio with access to BCBS companies to deploy innovation at scale. Sandbox is an independent company that provides healthcare-related investment management exclusively for the Blue Venture Fund.
The Blue Venture Fund is a strategic investment vehicle that aims to foster innovation within the healthcare system.
Managing Director
2019
Sandbox invests in technologies that drive lasting change in human livelihood and transform healthcare, sustainability and insurance & financial services. Sandbox also provides innovation consulting through Sandbox Advisors. Sandbox Clinical Ventures focuses on accelerating clinical innovation by investing in companies with transformative diagnostic, device and lab technologies. We bring together key stakeholders across the strategic and investment landscape to back companies that can improve the health of populations, reimagine the experience of care, and bend the cost curve.
Sandbox bridges the gap between startups and corporations in three ways: strategic venture funds, accelerators, and consulting services.
Board Member
2020
Onc.AI is a software that specializes in clinical oncology, genomics, proteomics, and radiomics.
Raised $33,000,000.00 from National Cancer Institute.
Board Member
2021
Board Observer
2021
SonarMD provides care management for chronic conditions that use drugs.
Raised $15,344,729.00 from K50 Ventures, The Blue Venture Fund and Arboretum Ventures.
Board Member
2022
Limber is a digital health solution designed for employers, health plans, and providers.
Raised $11,000,000.00 from The Blue Venture Fund, Sandbox, Glenview Capital Management and Blue Cross Blue Shield Association.
Board Observer
2020
Board Observer
2019
Octave is a biotechnology company that uses precision medicine and scientific insights to treat patients with multiple sclerosis.
Raised $91,000,070.00 from Michael J. Fox Foundation.
Adjunct Clinical Faculty, Dept. of Radiology
2019
Venture Scholar
2019 - 2019
Flare Capital Partners provides capital for early-stage and emerging healthcare technology companies.